TL;DR: Aetna modified CPB 0483, its anthrax vaccine and treatment coverage policy, effective September 26, 2025. Here's what billing teams need to know before submitting claims with CPT 90581.
Aetna, a CVS Health company, updated CPB 0483 governing anthrax vaccine and treatment coverage. The Aetna anthrax vaccine coverage policy directly affects claims filed under CPT 90581 — the anthrax vaccine code for subcutaneous or intramuscular use — along with three ICD-10-CM diagnosis codes. If your practice or facility bills for anthrax vaccination or treats patients with confirmed or suspected anthrax exposure, this policy change is on your radar as of September 26, 2025.
Quick-Reference Table
| Field | Detail |
|---|---|
| Payer | Aetna, a CVS Health company |
| Policy | Anthrax Vaccine/Treatment — CPB 0483 |
| Policy Code | CPB 0483 |
| Change Type | Modified |
| Effective Date | September 26, 2025 |
| Impact Level | Low–Medium (niche volume, but high-stakes when claims do occur) |
| Specialties Affected | Infectious disease, occupational medicine, public health, emergency medicine, travel medicine |
| Key Action | Audit your charge capture for CPT 90581 and confirm ICD-10-CM pairing with A22.1, Z20.810, or Z23 before submitting claims under this updated policy |
Aetna Anthrax Vaccine Coverage Criteria and Medical Necessity Requirements 2025
The CPB 0483 Aetna system policy covers anthrax vaccination and treatment under specific, narrow indications. This isn't a high-volume area for most practices, but when these claims come up — post-exposure prophylaxis, pre-exposure vaccination for at-risk workers, or treatment following confirmed pulmonary anthrax — denials are expensive and the clinical stakes are serious.
What Aetna Covers Under CPB 0483
The policy addresses three primary coverage scenarios. Each maps to a distinct ICD-10-CM code, so your code pairing on the claim matters as much as the procedure code itself.
Pre-exposure vaccination targets individuals with a documented occupational or environmental risk. This is the Z23 scenario — an encounter for immunization. Think laboratory workers handling Bacillus anthracis, military personnel under specific deployment protocols, or certain veterinary and agricultural workers with direct exposure risk. Medical necessity for this group depends on documented occupational exposure risk, not simply a patient request.
Post-exposure prophylaxis applies when a patient has confirmed or suspected contact with anthrax. This maps to Z20.810 — contact with and suspected exposure to anthrax. Claims filed here should reflect the exposure event in the documentation, not just the administration of the vaccine. Prior authorization requirements may apply depending on the patient's plan, so verify before you administer and bill.
Treatment of active anthrax infection — specifically pulmonary anthrax, coded A22.1 — falls under the policy's treatment provisions. Inhalation anthrax carries the highest mortality risk, which is why it has its own ICD-10-CM code. Claims for anthrax treatment in confirmed inhalation cases should reflect the severity of the clinical presentation in the medical record.
Intravenous Human Anthrax Immune Globulin (Anthrasil) — A Critical Note
The policy data flags a specific carve-out: intravenous human anthrax immune globulin — brand name Anthrasil — is in a "no separate reimbursement" group under CPT 90581's associated policy language. This tells you something important. CPT 90581 describes the anthrax vaccine for subcutaneous or intramuscular use. Anthrasil is a different product — an immune globulin administered intravenously, not the vaccine itself.
If your team bills Anthrasil under CPT 90581, that's a mismatch. Anthrasil requires a separate billing pathway, and the policy language suggests Aetna does not cover it as a standalone line item alongside or in place of CPT 90581. The real issue here is code-to-product alignment. Anthrax vaccine billing under CPT 90581 is only appropriate when the actual anthrax vaccine — not Anthrasil — was administered. Talk to your compliance officer if your facility stocks both and your billing team isn't clear on the distinction. A claim denial on Anthrasil is avoidable if you catch the mismatch at charge capture.
Prior Authorization Under CPB 0483
The policy does not specify a blanket prior authorization requirement, but that doesn't mean your patient's specific plan is prior-auth free. Aetna plan designs vary — some self-insured employer plans add prior auth requirements on top of the base coverage policy. For post-exposure prophylaxis especially, where urgency is real, call to verify prior authorization status before or immediately after administration. Document the auth number in the claim record.
Coverage Indications at a Glance
| Indication | Status | Relevant Codes | Notes |
|---|---|---|---|
| Pre-exposure vaccination (occupational/environmental risk) | Covered when medically necessary | CPT 90581, ICD-10 Z23 | Document occupational risk clearly; medical necessity must be established |
| Post-exposure prophylaxis (suspected/confirmed exposure) | Covered | CPT 90581, ICD-10 Z20.810 | Prior auth may apply by plan; verify before billing |
| Active pulmonary anthrax treatment | Covered | CPT 90581, ICD-10 A22.1 | Clinical documentation of severity required |
| Intravenous anthrax immune globulin (Anthrasil) billed under CPT 90581 | Not separately reimbursed under this code | CPT 90581 (mismatch) | Anthrasil is not the anthrax vaccine; requires separate billing pathway if covered at all |
Aetna Anthrax Vaccine Billing Guidelines and Action Items 2025
The volume on anthrax claims is low, but the margin for error is high. When these claims do come through, they tend to attract scrutiny. These billing guidelines apply starting September 26, 2025.
| # | Action Item |
|---|---|
| 1 | Audit your charge capture for CPT 90581 immediately. Confirm your charge description master (CDM) entry for CPT 90581 is labeled correctly as the anthrax vaccine for subcutaneous or intramuscular use — not as a catch-all for any anthrax-related product. If your facility stocks Anthrasil, it needs its own separate billing line. |
| 2 | Train your coding team on the three ICD-10-CM codes this policy covers. A22.1 is pulmonary anthrax. Z20.810 is contact with and suspected exposure to anthrax. Z23 is encounter for immunization. Each code signals a different clinical scenario to the payer. A mismatch between the ICD-10 code and the clinical documentation is the fastest path to a claim denial under this policy. |
| 3 | Do not bill CPT 90581 for Anthrasil administrations. This is the single highest-risk billing error under CPB 0483. If your clinical team administers Anthrasil — a separate biologic product — and your billing team codes it as CPT 90581, you're billing the wrong product to the wrong code. Aetna's policy flags this specifically. Review any historical claims where Anthrasil was administered and CPT 90581 was billed. |
| 4 | Verify prior authorization at the plan level, not just at the policy level. CPB 0483 is the base policy, but individual Aetna plan designs can layer on additional requirements. For post-exposure prophylaxis situations, build a workflow that lets your team verify prior auth quickly — ideally before administration or within 24 hours for emergency situations. Document everything. |
| 5 | Update your internal billing guidelines to reflect the September 26, 2025 effective date. If your team maintains a payer-specific billing guide or billing rules engine, flag the CPB 0483 modification. Any claim for anthrax vaccine or treatment submitted to Aetna on or after September 26, 2025 should align with the updated policy language. |
| 6 | Loop in your compliance officer if your facility treats anthrax in any volume. This is a narrow but high-stakes coverage area. If you work in an occupational medicine clinic serving industrial or agricultural clients, or if your emergency department has protocols for bioterrorism events, your compliance officer should review your anthrax billing workflows against CPB 0483 before the next claim goes out. |
| Previous Version | Current Version |
|---|---|
| Coverage is considered experimental and investigational for all indications | Coverage is considered medically necessary when specific criteria are met |
| Prior authorization is not required | Prior authorization is required for initial treatment |
| Documentation must include clinical history | Documentation must include clinical history |
| Re-review every 24 months | Re-review every 12 months with updated clinical documentation |
CPT, HCPCS, and ICD-10 Codes for Anthrax Vaccine/Treatment Under CPB 0483
Covered CPT Codes (When Medical Necessity Criteria Are Met)
| Code | Type | Description |
|---|---|---|
| 90581 | CPT | Anthrax vaccine, for subcutaneous or intramuscular use |
Flagged / Non-Separately Reimbursed Indications
| Code | Type | Description | Reason |
|---|---|---|---|
| 90581 (when billed for Anthrasil) | CPT | Anthrax vaccine, for subcutaneous or intramuscular use | Intravenous human anthrax immune globulin (Anthrasil) is not separately reimbursed under this code — product-to-code mismatch |
Key ICD-10-CM Diagnosis Codes
| Code | Description |
|---|---|
| A22.1 | Pulmonary anthrax |
| Z20.810 | Contact with and (suspected) exposure to anthrax |
| Z23 | Encounter for immunization |
Get the Full Picture for CPT 90581
Track this policy across versions, search 1,500+ policies by CPT code, and get real-time alerts when any payer changes coverage.